在BCG不响应的非肌肉侵入性膀癌中IL-15超激素NAI.
Karim Chamie1, Sam S Chang2, Eugene Kramolowsky3
1Department of Urology, UCLA Medical Center, Los Angeles.
NEJM evidence
|February 6, 2024
概括
与BCG结合的Nogapendekin alfa inbakicept (NAI) 在BCG不响应的膀癌症中表现有前途,实现完整的反应和高生存率. 这种组合疗法为治疗选择有限的患者提供了潜在的新选择.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 非肌肉侵入性膀癌 (NMIBC) 没有对Bacillus CalmetteGuérin (BCG) 的反应,具有有限的治疗途径.
- 介素-15 (IL-15) 超级激素诺加丁基因 alfa inbakicept (NAI) 可能通过免疫激活来增强BCG的疗效.
研究的目的:
- 在BCG不响应NMIBC的患者中评估内NAI与BCG结合的疗效和安全性.
- 评估完整反应 (CR) 率,耐久性和生存结果.
主要方法:
- 这是一项开放式的多中心研究,涉及BCG不响应 carcinoma in situ (CIS) 或乳头NMIBC的患者.
- 治疗臂包括内NAI加BCG (A队列) 或仅NAI (C队列),以及NAI加BCG用于高等级Ta/T1NMIBC (B队列).
- 主要终点是3个月或6个月访问后的CR (A/C队列) 和12个月后的无病生存期 (DFS) (B队列).
主要成果:
- 队列A (NAI + BCG) 在3个月或6个月的访问中实现了71%的CR率,CR的中位持续时间为26.6个月.
- 在24个月后,CR中的患者显示了避免囊切除的89.2%的概率和100%的疾病特异性存活率 (DSS).
- 队列B (高等级Ta/T1NMIBC) 显示了12个月DFS率为55.4%,NAI+BCG.
结论:
- 与NAI和BCG的组合疗法在BCG不响应的NMIBC,包括CIS中显示出显著的疗效.
- 治疗导致持久的完整反应,高率的囊切除术避免,以及出色的膀癌特异性生存率.
- NAI加BCG代表了对具有挑战性的NMIBC患者的有前途的新疗法策略.
相关概念视频
Tumor Immunotherapy
526
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
526
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


